BR112013027150A2 - thera - Google Patents

thera

Info

Publication number
BR112013027150A2
BR112013027150A2 BR112013027150A BR112013027150A BR112013027150A2 BR 112013027150 A2 BR112013027150 A2 BR 112013027150A2 BR 112013027150 A BR112013027150 A BR 112013027150A BR 112013027150 A BR112013027150 A BR 112013027150A BR 112013027150 A2 BR112013027150 A2 BR 112013027150A2
Authority
BR
Brazil
Prior art keywords
grf
growth hormone
analogues
leucine
releasing factor
Prior art date
Application number
BR112013027150A
Other languages
English (en)
Portuguese (pt)
Inventor
Habi Abdelkrim
G Peri Krishna
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BR112013027150A2 publication Critical patent/BR112013027150A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013027150A 2011-04-21 2012-04-17 thera BR112013027150A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477775P 2011-04-21 2011-04-21
PCT/CA2012/050242 WO2012142706A1 (en) 2011-04-21 2012-04-17 Growth hormone releasing factor (grf) analogs and uses thereof

Publications (1)

Publication Number Publication Date
BR112013027150A2 true BR112013027150A2 (pt) 2017-06-06

Family

ID=47021786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013027150A BR112013027150A2 (pt) 2011-04-21 2012-04-17 thera

Country Status (10)

Country Link
US (1) US8361964B2 (https=)
EP (1) EP2699591A4 (https=)
JP (1) JP6113144B2 (https=)
KR (1) KR20140027284A (https=)
CN (1) CN103547591A (https=)
AR (1) AR087727A1 (https=)
BR (1) BR112013027150A2 (https=)
CA (1) CA2833434A1 (https=)
MX (1) MX2013012259A (https=)
WO (1) WO2012142706A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
CN109153712B (zh) 2016-04-19 2022-09-16 格里芬制药国际公司 Peg化生物活性肽及其用途
US20230270865A1 (en) * 2020-07-05 2023-08-31 Theratechnologies Inc. Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4617149A (en) 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4801456A (en) 1987-07-09 1989-01-31 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
EP0307860B1 (en) * 1987-09-18 1994-06-08 F. Hoffmann-La Roche Ag Cyclic GRF-analogs
CA2040649A1 (en) * 1990-04-24 1991-10-25 Gerald S. Brooke Growth hormone releasing factor analogs
AU662731B2 (en) 1991-04-09 1995-09-14 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5262519A (en) 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
JP3576170B2 (ja) 1995-05-26 2004-10-13 セラテクノロジーズ・インコーポレーテッド 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
AU9558901A (en) 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
JP3996897B2 (ja) * 2001-06-08 2007-10-24 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチン−ドーパミンキメラ類似体
WO2004027064A2 (en) 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
AU2004281084B2 (en) 2003-10-20 2010-08-12 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
EP1812048A4 (en) 2004-10-20 2012-01-18 Theratechnologies Inc GH SECRETAGOGA AND ITS USE
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20100267636A1 (en) 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy

Also Published As

Publication number Publication date
MX2013012259A (es) 2013-11-22
US8361964B2 (en) 2013-01-29
AR087727A1 (es) 2014-04-16
JP2014515751A (ja) 2014-07-03
WO2012142706A1 (en) 2012-10-26
EP2699591A1 (en) 2014-02-26
KR20140027284A (ko) 2014-03-06
CN103547591A (zh) 2014-01-29
CA2833434A1 (en) 2012-10-26
JP6113144B2 (ja) 2017-04-12
EP2699591A4 (en) 2014-05-07
US20120270784A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
PH12014502778A1 (en) Antibody formulation
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
BR112012032282A2 (pt) administração transdérmica de memantina
BR112014026057A2 (pt) análogos limitados por anel como inibidores de arginase
EP2799543A4 (en) HUMANIZED ANTI-EPIREGULIN ANTIBODY AND CANCER THERAPY AGENTS WITH THESE ANTIBODY AS ACTIVE AGENT
CL2015001256A1 (es) Compuestos derivados del acido indaniloxi-dihidro-benzofuranil-acetico, agonistas del receptor acoplado a proteinas g40 (gpr40); sal; composicion farmaceutica; y uso para profilaxis y/o terapia de enfermedades metabolicas tales como diabetes y sus afecciones asociadas tales como resistencia a la insulina y obesidad, entre otras.
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
IL216466B (en) Compositions for respiratory delivery of active agents and associated methods and systems
BR112014018475A8 (pt) Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112013014616A2 (pt) sistema terapêutico transdérmico para a administração de uma substância ativa
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2014000289A1 (es) Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
BR112013027150A2 (pt) thera
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
AR118842A2 (es) Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12/02/2019.